Table 3.

Relationship of ALI with response rate, disease control rate, time-on-treatment and of immunotherapy-treated NSCLC patients

	Cohort A (IO-monotherapy, n = 460)		Cohort B (Chemo-immunotherapy, n = 212)
	ORR %	P	ORR %	P
ALI > 18	36 versus 24	0.008	43 versus 42	0.90
NLR < 5	37 versus 23	0.001	43 versus 42	0.84
PD-L1 TPSa	44 versus 22 versus 14	<0.001	50 versus 41 versus 38	0.43

	DCR %	P	DCR %	P
ALI > 18	65 versus 46	<0.001	77 versus 74	0.60
NLR < 5	66 versus 45	<0.001	75 versus 75	0.91
PD-L1 TPSa	68 versus 41 versus 49	<0.001	77 versus 73 versus 78%	0.74

	TOT HR (95% CI)	P	TOT HR (95% CI)	P
ALI > 18	0.52 (0.41-0.65)	<0.001	0.64 (0.42-0.97)	0.034
NLR < 5	0.56 (0.44-0.70)	<0.001	0.82 (0.54-1.23)	0.33
PD-L1 TPS 1-49%	1.08 (0.78-1.48)	0.65	0.92 (0.56-1.53)	0.76
PD-L1 TPS ≥50%	0.66 (0.48-0.91)	0.011	0.88 (0.49-1.57)	0.66

The association of each factor with overall survival (OS) was analyzed with a univariable Cox regression. ALI and the NLR were dichotomized at the bibliographic cut-offs of 18 and 5 respectively, which corresponded to the median values of our untreated patients (see Patients and methods in the main text). The PD-L1 tumor proportion score was divided in three categories (0/1-49/50+) and included as a categorical variable with 0 as the reference. The ECOG PS was divided in 0/1/>1 and included as a categorical variable with 0 as the reference.

ALI, advanced lung cancer inflammation index, CI, confidence interval; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; IO, immunotherapy; NLR, neutrophil-to-lymphocyte ratio, ORR, objective response rate; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.

^aPD-L1 TPS ≥50% versus 1-49% versus <1%.